drugset

drugset / Trial / NCT07211542

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

NCT07211542 ↗

Phase 2 Recruiting 75 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.

Timeline

Start: 2025-11-07
Primary completion: 2026-09
Completion: 2027-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1905	Monoclonal antibody	—	—

Indications